INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors.


Journal

Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693

Informations de publication

Date de publication:
02 2022
Historique:
received: 01 12 2020
revised: 13 07 2021
accepted: 15 09 2021
pubmed: 22 9 2021
medline: 15 3 2022
entrez: 21 9 2021
Statut: ppublish

Résumé

Cyclin-dependent kinases 4 and 6 (CDK4/6) represent a major therapeutic vulnerability for breast cancer. The kinases are clinically targeted via ATP competitive inhibitors (CDK4/6i); however, drug resistance commonly emerges over time. To understand CDK4/6i resistance, we surveyed over 1,300 breast cancers and identified several genetic alterations (e.g.,

Identifiants

pubmed: 34544752
pii: 2159-8290.CD-20-1726
doi: 10.1158/2159-8290.CD-20-1726
pmc: PMC8831444
mid: NIHMS1743297
doi:

Substances chimiques

Antineoplastic Agents 0
Cyclin-Dependent Kinase Inhibitor Proteins 0
Piperazines 0
Protein Kinase Inhibitors 0
Pyridines 0
Tumor Suppressor Proteins 0
palbociclib G9ZF61LE7G

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

356-371

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA234361
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA247749
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM132386
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA217694
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM121505
Pays : United States

Informations de copyright

©2021 The Authors; Published by the American Association for Cancer Research.

Références

Cell. 2007 Jan 26;128(2):269-80
pubmed: 17254966
Oncogene. 2017 Apr 20;36(16):2255-2264
pubmed: 27748766
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Genes Dev. 1993 May;7(5):812-21
pubmed: 8491378
Leukemia. 2009 Sep;23(9):1614-21
pubmed: 19369965
Drug Discov Today Technol. 2019 Apr;31:15-27
pubmed: 31200855
Cell Rep. 2013 Dec 26;5(6):1704-13
pubmed: 24332856
Nat Commun. 2018 Dec 5;9(1):5200
pubmed: 30518851
Genes Dev. 2000 Dec 15;14(24):3115-25
pubmed: 11124804
Cell Chem Biol. 2019 Feb 21;26(2):300-306.e9
pubmed: 30595531
Nat Med. 2019 Dec;25(12):1938-1947
pubmed: 31792461
Cell Chem Biol. 2018 Jan 18;25(1):78-87.e5
pubmed: 29129718
Ann Oncol. 2018 Mar 1;29(3):640-645
pubmed: 29236940
Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2070-5
pubmed: 18227510
J Comput Chem. 2004 Jul 15;25(9):1157-74
pubmed: 15116359
J Med Chem. 2006 Jun 29;49(13):3826-31
pubmed: 16789739
Cancer Cell. 2018 Sep 10;34(3):427-438.e6
pubmed: 30205045
Mol Cell Biol. 2000 Apr;20(7):2581-91
pubmed: 10713180
Nat Rev Drug Discov. 2004 Dec;3(12):1001-10
pubmed: 15573099
Cancer Cell. 2018 Dec 10;34(6):893-905.e8
pubmed: 30537512
Science. 2019 Dec 13;366(6471):
pubmed: 31831640
Cell Rep. 2019 Mar 5;26(10):2667-2680.e7
pubmed: 30840889
J Chem Theory Comput. 2015 Aug 11;11(8):3696-713
pubmed: 26574453
Cancer Discov. 2020 Aug;10(8):1174-1193
pubmed: 32404308
Cancer Cell. 2013 Aug 12;24(2):167-81
pubmed: 23948297
Int J Clin Exp Pathol. 2012;5(3):187-94
pubmed: 22558472
Cancer Discov. 2020 Jan;10(1):72-85
pubmed: 31594766
Mol Pharm. 2019 Sep 3;16(9):3842-3852
pubmed: 31329454
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Nat Commun. 2019 Mar 26;10(1):1373
pubmed: 30914635
Nucleic Acids Res. 2000 Jan 1;28(1):235-42
pubmed: 10592235
Oncotarget. 2016 Nov 22;7(47):77838-77853
pubmed: 27788482
Mol Cell Biol. 1995 May;15(5):2672-81
pubmed: 7739547
Nat Cell Biol. 2012 Dec;14(12):1322-9
pubmed: 23143395
Cell Cycle. 2015;14(8):1252-9
pubmed: 25695927
Mol Cell Biol. 1999 Mar;19(3):1775-83
pubmed: 10022865
J Biol Chem. 1997 Oct 10;272(41):25863-72
pubmed: 9325318
J Comput Chem. 2002 Dec;23(16):1623-41
pubmed: 12395429
Biophys J. 2015 Oct 20;109(8):1528-32
pubmed: 26488642
Genes Dev. 1997 Feb 15;11(4):492-503
pubmed: 9042862
Nature. 2016 Jun 22;535(7611):252-7
pubmed: 27338790
Angew Chem Int Ed Engl. 2019 May 6;58(19):6321-6326
pubmed: 30802347
Clin Cancer Res. 2014 May 1;20(9):2249-56
pubmed: 24789032
PLoS Comput Biol. 2017 Jul 26;13(7):e1005659
pubmed: 28746339
Nature. 2018 Nov;563(7730):265-269
pubmed: 30401838
Cancer Discov. 2017 Mar;7(3):277-287
pubmed: 27986707
Mol Cancer Ther. 2020 Oct;19(10):2221-2232
pubmed: 32747423
Nat Commun. 2020 Aug 26;11(1):4268
pubmed: 32848159
Mol Cancer Ther. 2004 Nov;3(11):1427-38
pubmed: 15542782
Genes Dev. 1997 Apr 1;11(7):847-62
pubmed: 9106657
Cancer Treat Rev. 2016 Apr;45:129-38
pubmed: 27017286
Nature. 2016 Apr 7;532(7597):127-30
pubmed: 26909574
Nat Rev Clin Oncol. 2016 Jul;13(7):417-30
pubmed: 27030077
Oncotarget. 2015 Jan 20;6(2):696-714
pubmed: 25557169
Nat Med. 2019 Feb;25(2):284-291
pubmed: 30559419
J Mol Graph Model. 2006 Oct;25(2):247-60
pubmed: 16458552
Nature. 1998 Sep 17;395(6699):237-43
pubmed: 9751050
Expert Opin Drug Discov. 2019 Dec;14(12):1255-1268
pubmed: 31538491
Blood. 1997 Jul 1;90(1):126-37
pubmed: 9207446
Mol Cancer Ther. 2016 Oct;15(10):2273-2281
pubmed: 27496135
J Comput Chem. 2015 Jun 5;36(15):1132-56
pubmed: 25914306
Cancer Cell. 2011 Jan 18;19(1):58-71
pubmed: 21215704
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821

Auteurs

Qing Li (Q)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Baishan Jiang (B)

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts.

Jiaye Guo (J)

Computational & Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Hong Shao (H)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Isabella S Del Priore (IS)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Qing Chang (Q)

Anti-Tumor Assessment, Memorial Sloan Kettering Cancer Center, New York, New York.

Rei Kudo (R)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Zhiqiang Li (Z)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Pedram Razavi (P)

Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Weill Cornell Medical College, New York, New York.

Bo Liu (B)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Andrew S Boghossian (AS)

Broad Institute of MIT and Harvard, Cambridge, Massachusetts.

Matthew G Rees (MG)

Broad Institute of MIT and Harvard, Cambridge, Massachusetts.

Melissa M Ronan (MM)

Broad Institute of MIT and Harvard, Cambridge, Massachusetts.

Jennifer A Roth (JA)

Broad Institute of MIT and Harvard, Cambridge, Massachusetts.

Katherine A Donovan (KA)

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts.

Marta Palafox (M)

Vall d'Hebron Institute of Oncology, Barcelona, Spain.

Jorge S Reis-Filho (JS)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

Elisa de Stanchina (E)

Anti-Tumor Assessment, Memorial Sloan Kettering Cancer Center, New York, New York.

Eric S Fischer (ES)

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts.

Neal Rosen (N)

Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York.

Violeta Serra (V)

Vall d'Hebron Institute of Oncology, Barcelona, Spain.

Andrew Koff (A)

Program in Molecular Biology, Memorial Sloan Kettering Cancer Center, New York, New York.

John D Chodera (JD)

Computational & Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Nathanael S Gray (NS)

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts.

Sarat Chandarlapaty (S)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. chandars@mskcc.org.
Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Weill Cornell Medical College, New York, New York.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH